Atlas Trials

Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

Clinical trial NCT06625970 · RECRUITING

Trial details

NCT number
NCT06625970
Sponsor
UNICANCER
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
High Risk Prostate CarcinomaProstate Cancer
Start date
2025-04-10
Primary completion
2033-10-01
Enrollment
700

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.